CVS Health's Medicaid business is experiencing medical cost pressure from higher-than-expected acuity following the ...

It is a scary situation no baby should ever be in, being left alone in a car with no parents or guardians around.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Shares of CVS Health Corp. CVS inched 0.11% higher to $45.82 Monday, on what proved to be an all-around mixed trading session ...

A customer who was in a CVS parking lot in Wyandotte noticed the baby alone, strapped in the back seat of a booster seat.

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price ...

All of the commercial prescriptions dispensed at CVS pharmacies will be processed through its CostVantage reimbursement model ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Zydus Lifesciences Ltd enters an agreement with CVS Caremark to add Zituvio, Zituvimet, and Zituvimet XR tablets for diabetes ...

The latest trading day saw CVS Health (CVS) settling at $44.49, representing a -0.96% change from its previous close. Recently, Zacks.com users have been paying close attention to CVS Health (CVS).

CVS Health has announced that starting this year, all commercial prescriptions dispensed through CVS Pharmacy will be contracted through its new CVS CostVantage reimbursement model.